Screen Shot 2018-10-26 at 2.02.39 PM.png

About the Study


We know that enrolling in a clinical study is an important and personal choice, and we're committed to making participation as easy as possible. 

Our priority is supporting patients and their caregivers as they seek a solution to recurrent C. difficile.

  • No colonoscopy, no enema, no bowel prep. The study treatment is a pill – not another invasive procedure.

  • Dedicated medical care. Participants will have regular visits with clinical staff and can receive the results at the end of the study.

  • Free transportation and coverage of study-related costs. We’re committed to ensuring that all participants can easily access study-related care.

  • All participants may be eligible to receive the study drug.  Any patient who experiences a recurrence during the study will have the opportunity to qualify for the investigational treatment.

  • Help solve recurrent C. difficileBe part of the community working toward a long-term solution.


What to Expect

Before joining the PRISM 3 study, you will be screened to find out if you are eligible. If you are eligible and choose to enroll you will:

  • Meet with your participating doctor to be randomly assigned to receive either a single dose of the study drug or a placebo (no active ingredients)

  • Have 7 visits with dedicated and experienced clinical staff over the next six months, who will evaluate your health and progress

  • Collect stool samples throughout the study (using the provided, at-home collection kits)

All study-related expenses, including transportation, medical testing, and clinical care, will be provided at no cost.

What if I experience a recurrence?

Whether you are given the study drug or a placebo, you may be eligible to receive the capsule with active ingredients if you experience an episode of C. difficile infection within 8 weeks of starting the study. This will be part of an “open label extension study” – a way to make sure that patients who experience recurrences have the opportunity to receive the investigational medication.

Have additional questions?

Please feel free to contact the study team with any questions we can help answer using this form.


Ready to join?


Share the Study